Literature DB >> 6641096

Enprofylline kinetics in healthy subjects after single doses.

O Borgå, K E Andersson, L E Edholm, P O Fagerström, E Lunell, C G Persson.   

Abstract

The kinetics of enprofylline, a novel antiasthmatic xanthine derivative, were studied. Eight healthy subjects received three different single enprofylline doses, 0.5, 1, and 1.5 mg/kg, injected as an infusion over 10 min. Plasma and urine levels of unchanged enprofylline were observed 3 to 7 and 21 to 24 hr after dosing. Plasma t 1/2 varied among individuals from 1.2 to 1.9 hr. Volume of distribution (V beta or area) and volume of distribution at steady state (V ss) averaged 0.57 and 0.511 X kg-1. Total clearance averaged 0.25 l X hr-1 X kg-1. Renal clearance ranged from 200 to 400 ml X min-1, indicating a large contribution by active tubular secretion. The mean recovery of unchanged drug in the urine was 89%. Thus, unlike theophylline, enprofylline was eliminated mainly by the kidney.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6641096     DOI: 10.1038/clpt.1983.252

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Creation of four consecutive instantaneous steady-state plasma concentration plateaus of theophylline and enprofylline by repeated infusions with exponentially decreasing delivery rates.

Authors:  J Kraan; L Borgström; G H Koëter; M Laseur; J H Jonkman; O E de Noord
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Respiratory and allergic disease. I.

Authors:  K F Chung; P J Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-02

3.  The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease.

Authors:  J Kraan; J H Jonkman; G H Koëter; C H Gips; P E de Jong; T W van der Mark; I Ekman; R A de Zeeuw
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Cardiovascular effects of two different xanthines in healthy subjects. Studies at rest, during exercise and in combination with a beta-agonist, terbutaline.

Authors:  T B Conradson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Pharmacokinetics of theophylline and enprofylline in patients requiring a high or low dose of theophylline.

Authors:  L C Laursen; N Johannesson; B Weeke
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Protein binding of enprofylline.

Authors:  K Tegnér; O Borgå; I Svensson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Enprofylline pharmacokinetics in children with asthma.

Authors:  C Hultqvist; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Enprofylline disposition in the presence and absence of amoxycillin or erythromycin.

Authors:  D S Sitar; F Y Aoki; D J Hoban; K G Hidinger; P R Montgomery; P A Mitenko
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

9.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Maximally effective plasma concentrations of enprofylline and theophylline during constant infusion.

Authors:  L C Laursen; N Johannesson; I Søndergaard; B Weeke
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.